Summary
Gilead Sciences, Inc. (GILD) announced the appointment of Javier J. Rodriguez to its Board of Directors, effective June 15, 2020. Mr. Rodriguez's appointment is a standard addition to the board and does not involve any disclosed related party transactions or special compensation arrangements outside of the company's regular non-employee director compensation programs. Mr. Rodriguez will receive compensation for his service, which includes a pro-rated equity grant consisting of stock options and restricted stock units, as well as a pro-rated cash retainer. This appointment signifies a routine governance update for Gilead, aimed at strengthening its board oversight.
Key Highlights
- 1Javier J. Rodriguez appointed to Gilead's Board of Directors, effective June 15, 2020.
- 2No disclosed arrangements or understandings between Mr. Rodriguez and other parties regarding his selection.
- 3No reportable related party transactions involving Mr. Rodriguez.
- 4Mr. Rodriguez will receive standard compensation for non-employee directors.
- 5Equity compensation includes a pro-rated grant of 8,667 stock options and 1,838 restricted stock units.
- 6Cash compensation includes a pro-rated retainer of $3,287.67 for service through June 30, 2020.
- 7Details on director compensation and the equity plan are available in the company's proxy statement and prior 8-K filing.
Frequently Asked Questions
Javier J. Rodriguez has been elected to serve on Gilead Sciences, Inc.'s Board of Directors.
Mr. Rodriguez will receive a pro-rated equity grant (8,667 stock options and 1,838 restricted stock units) and a pro-rated cash retainer of $3,287.67 for his service as a non-employee director.
No, the filing states there are no arrangements or understandings concerning his selection and no reportable related party transactions involving Mr. Rodriguez.
Details can be found in Gilead's Definitive Proxy Statement filed on March 24, 2020, and its Current Report on Form 8-K filed on May 12, 2017.